I’ve been teasing this for a very long time, and time has finally arrived…
I am incredibly excited to announce the launch of my very first book, Middle-Class Millionaire: From $80K in Debt to $3M in Profits through Catalyst Trading.
I truly believe that this book can serve as a blueprint for people that want transform their lives through the stock market.
Just 5 years ago, I was a broke college student with a small $15,000 trading account and no trading experience.
Today, I am here launching my very own book, where I’ve document how I turned that same $15,000 trading account into over $3,729,402 in trading profits.
Click here to get a digital copy of my book for less than a dollar!
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.
And now to today’s watchlist.
I took an initial position in CBAY today.
The market can’t seem to make up its mind recently. Still having big ranges. I’m doing my best to manage risk and lock in profits when our stocks pop.
It’s the last day of the month tomorrow and we have a 3-day weekend! So enjoy and let’s make sure we hit April running!
Just a reminder, charts and targets are updated every Monday morning!
New Catalyst Swing names (1 – 4 week holds) I am watching…
Cymabay Therapeutics (CBAY)
Catalyst Dates: Data due out at the EASL conference April 11-15
Buy Zone: $11.70 to $12.20
Profit Zone: $13.00 or higher
Stop Zone: $11.40 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
Karyopharm Therapeutics (KPTI)
Catalyst Dates: Phase 2b data due out at the end of April
Buy Zone: $13.50 to $14.50
Profit Zone: $16.00 or higher
Stop Zone: $13.00 or below
Corium International (CORI)
Catalyst Dates: Phase 1 data due likely in May
Buy Zone: $11.25 to $11.75
Profit Zone: $13.00 or higher
Stop Zone: $10.50 or below
AcelRx (ACRX)
Catalyst Dates: European approval likely due within next two months
Buy Zone: $2.00 to $2.20
Profit Zone: $2.50 or higher
Stop Zone: $1.80 or below
Exelixis (EXEL)
Catalyst Dates: Phase 3 cancer data due in the first half of 2018
Buy Zone: $24.00 to $25.00
Profit Zone: $27.00 or higher
Stop Zone: $23.40 or below
Neurocrine Biosciences (NBIX)
Catalyst Dates: FDA approval approximately April 27th
Buy Zone: $84.00 to $85.50
Profit Zone: $90.00 or higher
Stop Zone: $83.00 or below
Achaogen (AKAO)
Catalyst Dates: Advisory Committee meeting on May 2nd. FDA approval dateJune 25th.
Buy Zone: $11.25 to $12.00
Profit Zone: $13.00 or higher
Stop Zone: $10.75 or below
AVEO Pharmaceuticals (AVEO)
Catalyst Dates: Phase 3 data due out in the second quarter
Buy Zone: $2.80 to $3.00
Profit Zone: $3.50 or higher
Stop Zone: $2.60 or below
Pluristem (PSTI)
Catalyst Dates: Phase 2 data due out in the second quarter
Buy Zone: $1.35 to $1.45
Profit Zone: $1.75 or higher
Stop Zone: $1.20 or below
Kitov Pharma (KTOV)
Catalyst Dates: FDA Approval date of May 31
Buy Zone: $2.60 to $2.80
Profit Zone: $3.25 or higher
Stop Zone: $2.20 or below
TherapeuticsMD (TXMD)
Catalyst Dates: FDA approval date of May 29th
Buy Zone: $4.90 to $5.20
Profit Zone: $6.00 or higher
Stop Zone: $4.60 or below
Medicinova (MNOV)
Catalyst Dates: Phase 1b/2a abstract to be presented April 27th
Buy Zone: $10.50 to $11.00
Profit Zone: $12.00 or higher
Stop Zone: $10.15 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $25.00 to $27.00
Profit Zone: $30.00 or higher
Stop Zone: $24.00 or below
Rigel Pharmaceuticals (RIGL)
Catalyst Dates: FDA approval date of April 17th for immune thrombocytopenic purpura
Buy Zone: $3.50 to $3.90
Profit Zone: $4.50 or higher
Stop Zone: $3.40 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.50 to $6.00
Profit Zone: $8.00 or higher
Stop Zone: $5.20 or below
